Toronto, Ontario – TheNewswire - May 1, 2024 - Ventripoint Diagnostics Ltd. ("Ventripoint" or the "Company"), (TSXV:VPT); (OTC:VPTDF) is pleased to announce that Duke University Health Center has purchased its second VMS+ unit from Ventripoint , which processes ultrasound images of the heart to generate MRI-quality measurements in minutes.

Duke Health Center Arringdon, part of the Duke University Health System located in Durham, North Carolina. Duke Health, is affiliated with Duke University and is a world-class academic and health care system.

“Tools that allow us to reduce the cost and time needed for reliable diagnostics can potentially save the lives of infants, children and adults with heart conditions,” said Richard Krasuski, M.D., director of Duke’s Adult Congenital Heart Program.

Duke Children’s Hospital has been using Ventripoint’s VMS+ system for two years, focusing primarily on single ventricle paediatric patients. Now, the VMS+ will be implemented at Duke Cardiology Arringdon and will be used in real-time adult patient heart scans and help Duke further its study of Ventripoint’s potential.

“We are very excited to work with Duke Cardiology Arringdon on our latest VMS+ system for their cardiac clinic,” said Ventripoint Interim CEO, Hugh MacNaught. “We have had great success working with Duke for their children’s health clinic, and we are sure that the Adult Congenital Heart Disease program will also experience great results.”

The VMS+ provides diagnostic and treatment procedures, resulting in scans of all four chambers of the heart at a fraction of the cost and time needed for cardiac MRIs. The ease of use of Ventripoint’s A.I. technology also means that patients can receive numerous heart scans, to assist caregivers in treatment and patient monitoring.

As part of the purchase order, Ventripoint will update its software at Duke as the VMS+ advances its capabilities. Ventripoint’s VMS+  is now being used in hospitals in the U.S., Europe, the UK, and Canada.

Corporate Update

In addition to the above-described sale, over the past month the Company has completed and filed its audited financial statements, initiated an off-the-market financing, hosted meetings with its European distributor, prepared for the AEPC conference, refreshed its website and continued the development of VMS+4.0.

Conference Call Details

The Company will hold a conference call to discuss this progress.

Monday May 6th, 2024 at 4.00 pm Eastern Time

For expedited access to the call, use this registration link: https://dpregister.com/sreg/10023469/f8621ab066

Dial-in details will display on screen, and a calendar invitation will be sent by email. Registration will remain open through to the end of the call.

Participants who prefer to speak with an operator may dial 1-844-763-8274 or +1-647-484-8814. It is recommended that you call 10 minutes before the scheduled start time to avoid the queue.

After the call, an audio recording will be made available via telephone for one month, until end of day June 3rd. The recording can be accessed by dialing 1-855-669-9658 or +1-604-674-8052 and using the access code 0892#.  

A written transcript of the call will be available on Ventripoint’s website shortly after its conclusion.  

About Ventripoint Diagnostics Ltd.

Ventripoint is an industry leader in the application of AI (Artificial Intelligence) to echocardiography. Ventripoint's VMS products are powered by its proprietary Knowledge Based Reconstruction technology, which is the result of a decade of development and provides accurate volumetric cardiac measurements equivalent to MRI. This affordable, gold-standard alternative allows cardiologists greater confidence in the management of their patients. Providing better care to patients serves as a springboard and basic standard for all of Ventripoint's products that guide our future developments. In addition, VMS+ is versatile and can be used with all ultrasound systems from any vendor supported by regulatory market approvals in the U.S., Europe, and Canada.

For further information, please contact:

Jonathan Robinson

This email address is being protected from spambots. You need JavaScript enabled to view it.

416-669-1001

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this news release.

Forward Looking Statements

This news release contains forward-looking statements and forward-looking information within the meaning of applicable securities laws. The use of any of the words "expect", "anticipate", "continue", "estimate", "objective", "ongoing", "may", "will", "project", "should", "believe", "plans", "intends'' and similar expressions are intended to identify forward-looking information or statements. The forward-looking statements and information are based on certain key expectations and assumptions made by the Company. Although the Company believes that the expectations and assumptions on which such forward-looking statements and information are based are reasonable, undue reliance should not be placed on the forward-looking statements and information because the Company can give no assurance that they will prove to be correct.

Since forward-looking statements and information address future events and conditions, by their very nature they involve inherent risks and uncertainties. Actual results could differ materially from those currently anticipated due to a number of factors and risks. Factors which could materially affect such forward-looking information are described in the risk factors in the Company's most recent annual management's discussion and analysis that is available on the Company's profile on SEDAR at www.sedar.com. Readers are cautioned that the foregoing list of factors is not exhaustive. The forward-looking statements included in this news release are expressly qualified by this cautionary statement. The forward-looking statements and information contained in this news release are made as of the date hereof and the Company undertakes no obligation to update publicly or revise any forward-looking statements or information, whether as a result of new information, future events or otherwise, unless so required by applicable securities laws.